Revenue
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ptc Therapeutics, Inc. (PTCT)
Price$69.30Cached quote
Net income
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.73B | $806.8M | $937.8M | $698.8M | $538.6M | $380.8M | $307.0M | $264.7M | $194.4M | $82.7M | $36.8M | $25.2M | $34.7M | $33.9M | $105.4M |
| Gross profit | $1.68B | $749.4M | $872.3M | $654.1M | N/A | N/A | $294.8M | $252.1M | $189.8M | $82.7M | $36.8M | N/A | N/A | N/A | N/A |
| Gross margin | 97.28% | 92.89% | 93.02% | 93.61% | N/A | N/A | 96.05% | 95.21% | 97.65% | 100.00% | 100.00% | N/A | N/A | N/A | N/A |
| Research & development | $455.2M | $534.5M | $666.6M | $651.5M | $540.7M | $477.6M | $257.5M | $172.0M | $117.5M | $117.6M | $121.8M | $79.8M | $54.9M | $46.1M | $58.7M |
| Operating expenses | $863.7M | $1.11B | $1.38B | $1.15B | $913.0M | $812.5M | $548.1M | $380.4M | $258.7M | $214.8M | $203.9M | $124.7M | $80.1M | $60.8M | $74.8M |
| Operating income | $866.9M | −$302.6M | −$439.5M | −$447.4M | −$374.4M | −$431.8M | −$241.2M | −$115.7M | −$64.3M | −$132.1M | −$167.1M | −$99.4M | −$45.4M | −$26.8M | $30.6M |
| Operating margin | 50.09% | −37.50% | −46.86% | −64.03% | −69.52% | −113.39% | −78.56% | −43.70% | −33.07% | −159.67% | −454.58% | −393.79% | −130.85% | −78.97% | 29.01% |
| EBITDA | $905.8M | −$226.9M | −$202.9M | −$318.6M | −$310.3M | −$388.3M | −$209.0M | −$89.6M | −$46.6M | −$128.8M | −$164.3M | −$97.2M | −$43.0M | −$24.1M | $33.5M |
| EBITDA margin | 52.34% | −28.13% | −21.64% | −45.59% | −57.61% | −101.97% | −68.08% | −33.84% | −23.98% | −155.70% | −446.76% | −384.94% | −123.94% | −71.01% | 31.74% |
| Net income | $682.6M | −$363.3M | −$626.6M | −$559.0M | −$523.9M | −$438.2M | −$251.6M | −$128.1M | −$79.0M | −$142.1M | −$170.4M | −$93.8M | −$51.6M | −$26.2M | $30.9M |
| Net profit margin | 39.44% | −45.03% | −66.81% | −80.00% | −97.27% | −115.07% | −81.95% | −48.38% | −40.64% | −171.83% | −463.60% | −371.37% | −148.65% | −77.28% | 29.32% |
| Basic EPSper basic share | $8.58 | -$4.73 | -$8.37 | -$7.79 | -$7.43 | -$6.64 | -$4.27 | -$2.75 | -$2.02 | -$4.17 | -$5.07 | -$2.97 | -$5.18 | $219.76 | $23.95 |
| Diluted EPSper diluted share | $7.78 | -$4.73 | -$8.37 | -$7.79 | -$7.43 | -$6.64 | -$4.27 | -$2.75 | -$2.02 | -$4.17 | -$5.07 | -$2.97 | -$5.18 | $42.50 | $4.55 |
Owners
Reported shareholders
16.76%of listed shares
BlackRock, Inc.13.96M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 16.76%13.96M shares |
RTW INVESTMENTS, LP | 9.30%7.75M shares |
Jupiter Topco LLC | 8.68%7.24M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 5.91%4.93M shares |
STATE STREET CORP | 5.52%4.6M shares |
WELLINGTON MANAGEMENT GROUP LLP | 4.95%4.13M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.49%3.74M shares |
SCHMERTZLER MICHAEL | ≈3.31%2.76M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.65%2.21M shares |
TORONTO DOMINION BANK | 2.60%2.17M shares |
WESTFIELD CAPITAL MANAGEMENT CO LP | 2.35%1.96M shares |
Hood River Capital Management LLC | 2.09%1.74M shares |
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 2.07%1.72M shares |
D. E. Shaw & Co., Inc. | 1.86%1.55M shares |
TANG CAPITAL MANAGEMENT LLC | 1.80%1.5M shares |
BANK OF AMERICA CORP /DE/ | 1.74%1.45M shares |
Driehaus Capital Management LLC | 1.73%1.44M shares |
FMR LLC | 1.68%1.4M shares |
Jefferies Financial Group Inc. | 1.63%1.36M shares |
FULLER & THALER ASSET MANAGEMENT, INC. | 1.39%1.16M shares |
Percentages use 83.33M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Oct 21, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Sep 17, 2026Form 4 · 10b5-1 | SCHMERTZLER MICHAELDirector | SellCommon Stock · indirect | 376 | $68.45 | $25.7K | 1.30M |
| Sep 17, 2026Form 4 · 10b5-1 | SCHMERTZLER MICHAELDirector | SellCommon Stock · indirect | 9.6K | $67.83 | $652.8K | 1.30M |
| Sep 16, 2026Form 4 · 10b5-1 | SCHMERTZLER MICHAELDirector | SellCommon Stock · indirect | 7.0K | $67.35 | $471.9K | 1.31M |
| Sep 16, 2026Form 4 · 10b5-1 | SCHMERTZLER MICHAELDirector | SellCommon Stock · indirect | 3.0K | $66.58 | $199.3K | 1.31M |
| Sep 10, 2026Form 4 · 10b5-1 | SCHMERTZLER MICHAELDirector | SellCommon Stock · indirect | 10.0K | $67.34 | $673.4K | 1.32M |
Community posts
PTC raises its revenue forecast as Sephience sales expand
PTC Therapeutics ($PTCT) raised its full-year 2026 revenue expectation to $1.29–$1.32 billion and increased product-sales guidance to $960–$990 million from $850–$950 million. Third-quarter 2026 product and royalty revenue reached $357.6 mi ...
